Infrequent, low magnitude HIV-specific T cell responses in HIV-uninfected participants in the 1% tenofovir microbicide gel trial (CAPRISA004)
Journal Article
2012
Permanent link to this Item
Authors
Journal Title
Retrovirology
Link to Journal
Journal ISSN
Volume Title
Publisher
BioMed Central Ltd
Publisher
University of Cape Town
Department
Faculty
Series
Abstract
Macaque studies of antiretroviral-containing microbicide gels administered rectally or vaginally followed by SIV challenge have documented priming of SIV-specific T cell responses in the blood of protected animals. This concept has been termed “chemo-vaccination”, where aborted viral replication is thought to leave an immune footprint of exposure, which may augment protection provided by microbicides/PrEP. We investigated whether T cell responses were detectable in women participating in CAPRISA004 1% tenofovir microbicide trial, which showed 39% efficacy in reducing HIV acquisition.
Description
Reference:
Burgers, W. A., Muller, T. L., Kiravu, A., Naranbhai, V., Sibeko, S., Werner, L., ... & Karim, S. A. (2012). Infrequent, low magnitude HIV-specific T cell responses in HIV-uninfected participants in the 1% tenofovir microbicide gel trial (CAPRISA004). Retrovirology, 9(Suppl 2), P225.